Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression

NCT07929740 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT07929740 Not yet recruiting Phase 1 126 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07929740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started October 2026. Interventional study, Phase 1, 126 participants (estimated). Lead sponsor Kura Oncology, Inc.. Primary measures: To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts...; To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts... and 3 more.

How it compares

457 similar trials: same condition (Myelodysplastic Syndromes) and phase

Enrollment

This trial
126
Middle half
12 to 48
Median
24
Trials with a value
432

Months from start to completion

This trial
28
Middle half
30.5 to 72
Median
46.2
Trials with a value
433

Sites

This trial
Not reported
Middle half
1 to 5
Median
1
Trials with a value
443
Posted results or a linked paper 33% 153 of 457 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
February 28, 2029
Enrollment
126 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Recurrence

Registry terms: myelodysplastic syndrome (mds)/aml, myeloid leukemia, acute

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Kura Oncology, Inc.

Arms

As registered; 3 arms.

Registered arms
Arm Type Interventions
Cohort A Experimental Ziftomenib
Show registry wording

Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

Cohort B Experimental Ziftomenib
Show registry wording

Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

Cohort C Experimental Ziftomenib
Show registry wording

Sequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2)

Primary endpoints

Registered primary outcome measures; 5 primary.

Registered primary endpoints
Measure Time frame
To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) During the first 56 days of ziftomenib
Show registry wording

Maximum plasma concentration at steady state (Cmax,ss)

To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) During the first 56 days of ziftomenib
Show registry wording

Plasma concentration observed at end of dosing interval at steady state (Cτ)

To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) During the first 56 days of ziftomenib
Show registry wording

Area under the concentration-time curve from time 0 to dosing interval at steady state (AUC0-τ,ss)

To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) During the first 56 days of ziftomenib
Show registry wording

Time to Cmax,ss (Tmax,ss)

To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) During the first 56 days of ziftomenib
Show registry wording

Cavg,ss

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Ziftomenib 8 Orange Book patentsPatent cliff July 16, 2044 (Orange Book patent)
    • US 12410184; expires July 16, 2044; assignee Kura Oncology, Inc.
    • US 12521396; expires July 16, 2044; assignee not stated
    • US 11944627; expires September 6, 2038; assignee Kura Oncology, Inc.
    • US 10781218; expires March 15, 2037; assignee Kura Oncology, Inc., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    • US 11673898; expires March 15, 2037; assignee Kura Oncology, Inc., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    • +3 more patents

Lead sponsor's other trials

Kura Oncology, Inc., most recent start first.

Similar trials

Same condition (Myelodysplastic Syndromes) and phase, most recent start first.